GURUFOCUS.COM » STOCK LIST » Healthcare » Medical Devices & Instruments » Austar Lifesciences Ltd (HKSE:06118) » Definitions » EBIT

Austar Lifesciences (HKSE:06118) EBIT : HK$-22 Mil (TTM As of Dec. 2023)


View and export this data going back to 2014. Start your Free Trial

What is Austar Lifesciences EBIT?

Austar Lifesciences's earnings before interest and taxes (EBIT) for the six months ended in Dec. 2023 was HK$47 Mil. Its earnings before interest and taxes (EBIT) for the trailing twelve months (TTM) ended in Dec. 2023 was HK$-22 Mil.

EBIT or Operating Income is linked to Return on Capital for both regular definition and Joel Greenblatt's definition. Austar Lifesciences's annualized ROC % for the quarter that ended in Dec. 2023 was 6.84%. Austar Lifesciences's annualized ROC (Joel Greenblatt) % for the quarter that ended in Dec. 2023 was 22.92%.

EBIT is also linked to Joel Greenblatt's definition of earnings yield. Austar Lifesciences's Earnings Yield (Joel Greenblatt) % for the quarter that ended in Dec. 2023 was -2.91%.


Austar Lifesciences EBIT Historical Data

The historical data trend for Austar Lifesciences's EBIT can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

Austar Lifesciences EBIT Chart

Austar Lifesciences Annual Data
Trend Dec14 Dec15 Dec16 Dec17 Dec18 Dec19 Dec20 Dec21 Dec22 Dec23
EBIT
Get a 7-Day Free Trial Premium Member Only Premium Member Only 17.31 52.49 396.27 144.20 -22.37

Austar Lifesciences Semi-Annual Data
Jun14 Dec14 Jun15 Dec15 Jun16 Dec16 Jun17 Dec17 Jun18 Dec18 Jun19 Dec19 Jun20 Dec20 Jun21 Dec21 Jun22 Dec22 Jun23 Dec23
EBIT Get a 7-Day Free Trial Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only 85.75 60.59 86.47 -69.34 46.98

Competitive Comparison of Austar Lifesciences's EBIT

For the Medical Devices subindustry, Austar Lifesciences's EV-to-EBIT, along with its competitors' market caps and EV-to-EBIT data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.


Austar Lifesciences's EV-to-EBIT Distribution in the Medical Devices & Instruments Industry

For the Medical Devices & Instruments industry and Healthcare sector, Austar Lifesciences's EV-to-EBIT distribution charts can be found below:

* The bar in red indicates where Austar Lifesciences's EV-to-EBIT falls into.



Austar Lifesciences EBIT Calculation

EBIT, sometimes also called Earnings Before Interest and Taxes, is a measure of a firm's profit that includes all expenses except interest and income tax expenses. It is the difference between operating revenues and operating expenses. When a firm does not have non-operating income, then Operating Income is sometimes used as a synonym for EBIT and operating profit.

EBIT for the trailing twelve months (TTM) ended in Dec. 2023 adds up the semi-annually data reported by the company within the most recent 12 months, which was HK$-22 Mil.

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.


Austar Lifesciences  (HKSE:06118) EBIT Explanation

1. EBIT or Operating Income is linked to Return on Capital for both regular definition and Joel Greenblatt's definition.

Austar Lifesciences's annualized ROC % for the quarter that ended in Dec. 2023 is calculated as:

ROC % (Q: Dec. 2023 )
=NOPAT/Average Invested Capital
=Operating Income * ( 1 - Tax Rate % )/( (Invested Capital (Q: Jun. 2023 ) + Invested Capital (Q: Dec. 2023 ))/ count )
=102.258 * ( 1 - -4.24% )/( (1613.293 + 1503.181)/ 2 )
=106.5937392/1558.237
=6.84 %

where

Invested Capital(Q: Jun. 2023 )
=Total Assets - Accounts Payable & Accrued Expense - Excess Cash
=Total Assets - Accounts Payable & Accrued Expense - ( Cash, Cash Equivalents, Marketable Securities - max(0, Total Current Liabilities - Total Current Assets+Cash, Cash Equivalents, Marketable Securities))
=2518.125 - 767.135 - ( 137.697 - max(0, 1461.114 - 1875.363+137.697))
=1613.293

Invested Capital(Q: Dec. 2023 )
=Total Assets - Accounts Payable & Accrued Expense - Excess Cash
=Total Assets - Accounts Payable & Accrued Expense - ( Cash, Cash Equivalents, Marketable Securities - max(0, Total Current Liabilities - Total Current Assets+Cash, Cash Equivalents, Marketable Securities))
=2361.438 - 668.197 - ( 190.06 - max(0, 1288.129 - 1721.41+190.06))
=1503.181

Note: The Operating Income data used here is two times the semi-annual (Dec. 2023) data.

2. Joel Greenblatt's definition of Return on Capital:

Austar Lifesciences's annualized ROC (Joel Greenblatt) % for the quarter that ended in Dec. 2023 is calculated as:

ROC (Joel Greenblatt) %(Q: Dec. 2023 )
=EBIT/Average of (Net fixed Assets + Net Working Capital)
=EBIT/Average of (Property, Plant and Equipment+Net Working Capital)
     Q: Jun. 2023  Q: Dec. 2023
=EBIT/( ( (Property, Plant and Equipment + Net Working Capital) + (Property, Plant and Equipment + Net Working Capital) )/ count )
=93.952/( ( (401.823 + max(-241.361, 0)) + (417.848 + max(-226.508, 0)) )/ 2 )
=93.952/( ( 401.823 + 417.848 )/ 2 )
=93.952/409.8355
=22.92 %

where Working Capital is:

Working Capital(Q: Jun. 2023 )
=(Accounts Receivable + Total Inventories + Other Current Assets) - (Accounts Payable & Accrued Expense + Defer. Rev. + Other Current Liabilities)
=(421.93 + 360.465 + 93.042) - (767.135 + 0 + 349.663)
=-241.361

Working Capital(Q: Dec. 2023 )
=(Accounts Receivable + Total Inventories + Other Current Assets) - (Accounts Payable & Accrued Expense + Defer. Rev. + Other Current Liabilities)
=(382.011 + 265.963 + 49.186) - (668.197 + 0 + 255.471)
=-226.508

When net working capital is negative, 0 is used.

Note: The EBIT data used here is two times the semi-annual (Dec. 2023) EBIT data.

3. It is also linked to Joel Greenblatt's definition of Earnings Yield:

Austar Lifesciences's Earnings Yield (Joel Greenblatt) % for today is calculated as:

Earnings Yield (Joel Greenblatt) %=EBIT (TTM)/Enterprise Value (Q: Dec. 2023 )
=-22.366/768.486
=-2.91 %

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.


Austar Lifesciences EBIT Related Terms

Thank you for viewing the detailed overview of Austar Lifesciences's EBIT provided by GuruFocus.com. Please click on the following links to see related term pages.


Austar Lifesciences (HKSE:06118) Business Description

Traded in Other Exchanges
Address
No. 1018, Changning Road, Rooms 2010-2013, 20th Floor, Changning District, Shanghai, CHN
Austar Lifesciences Ltd is a China-based company engaged in providing engineering solutions to pharmaceutical manufacturers and research institutes. The business activity of the group is operated through Liquid and Bioprocess Systems; Clean Room and Automation Control and Monitoring Systems; Powder and Solid Systems; Good Manufacturing Practice (GMP) Compliance Service; Life Science Consumables; and Distribution and Agency of Pharmaceutical Equipment segments. It derives the majority of revenue from the Liquid and Bioprocess System segment which is involved in providing solutions in pharmaceutical and water systems to treat water. The geographical business presence of the firm is seen across China and in other countries.

Austar Lifesciences (HKSE:06118) Headlines

No Headlines